Ligand Pharmaceuticals Incorporated (LGND) Financial Ratios: P/E, ROE & More

Ligand Pharmaceuticals Incorporated (LGND) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Ligand Pharmaceuticals Incorporated had a P/E ratio of 29.90, return on equity of 13.5% (up from -0.5%), debt-to-equity of 0.44 (up from 0.01) and a current ratio of 22.23 (up from 8.93). A current ratio of 22.23 means current assets exceed current liabilities.

Ligand Pharmaceuticals Incorporated Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Valuation Ratios
P/E Ratio	29.90	-	23.88	-	45.18	-
Forward P/E	35.20	53.58	35.07	298.37	298.37	33.23
P/S Ratio	13.88	12.11	9.48	5.75	10.69	9.78
P/B Ratio	3.66	2.44	1.78	1.89	3.14	2.25
Price/Tangible Book	5.39	4.42	4.18	8.11	7.85	-
Price/FCF	76.09	21.26	27.04	8.99	36.86	31.90
Price/OCF	75.39	20.86	25.12	8.19	32.76	29.30
PEG Ratio	2.42	3.57	2.34	23.42	18.19	1.61
Enterprise Value Ratios
EV/Revenue	13.08	10.84	8.08	5.71	10.72	7.73
EV/EBITDA	43.32	31.11	22.90	27.11	22.09	18.31
EV/EBIT	74.32	78.73	108.04	369.11	39.07	30.77
EV/FCF	71.72	19.03	23.04	8.93	36.96	25.22
Profitability & Returns
Return on Equity (ROE)	13.47%	-0.53%	8.29%	-0.74%	9.98%	0.89%
Return on Assets (ROA)	2.36%	1.66%	0.79%	0.18%	3.11%	1.80%
Return on Invested Capital (ROIC)	5.61%	-6.59%	1.64%	-0.07%	8.50%	7.45%
Return on Capital Employed (ROCE)	3.10%	2.50%	1.30%	0.50%	5.30%	3.30%
Leverage & Solvency Ratios
Debt/Equity	0.44	0.01	0.01	0.15	0.40	0.64
Debt/EBITDA	5.52	0.12	0.13	2.09	2.74	6.42
Debt/FCF	9.23	0.07	0.13	0.70	4.63	9.11
Liquidity Ratios
Current Ratio	22.23	8.93	14.15	2.67	11.15	5.00
Quick Ratio	21.83	8.32	12.49	2.50	10.39	4.70
Efficiency Ratios
Asset Turnover	0.21	0.19	0.17	0.19	0.18	0.11
Inventory Turnover	8.24	1.71	1.88	4.38	3.50	4.20
Yield & Distribution Ratios
Earnings Yield	3.34%	-0.20%	4.19%	-2.96%	2.21%	-0.19%
FCF Yield	1.31%	4.70%	3.70%	11.12%	2.71%	3.13%
Buyback Yield	-10.96%	-3.00%	-5.27%	2.19%	-2.50%	14.84%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Ligand Pharmaceuticals Incorporated Financial Ratios

What is Ligand Pharmaceuticals Incorporated's P/E ratio?

Ligand Pharmaceuticals Incorporated's P/E ratio was 29.90 for fiscal 2025 (period ended Dec 31, 2025).

What is Ligand Pharmaceuticals Incorporated's return on equity?

Ligand Pharmaceuticals Incorporated's return on equity (ROE) was 13.5% for fiscal 2025 (period ended Dec 31, 2025). It was -0.5% a year earlier.

What is Ligand Pharmaceuticals Incorporated's debt-to-equity ratio?

Ligand Pharmaceuticals Incorporated's debt-to-equity ratio was 0.44 for fiscal 2025 (period ended Dec 31, 2025). It was 0.01 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition